SK285344B6 - Použitie cis-N-cyklohexyl-N-etyl-[3-(3-chlór-4- cyklohexylfenyl)alyl]amínu na prípravu farmacetických kompozícií na liečbu proliferatívnych chorôb - Google Patents
Použitie cis-N-cyklohexyl-N-etyl-[3-(3-chlór-4- cyklohexylfenyl)alyl]amínu na prípravu farmacetických kompozícií na liečbu proliferatívnych chorôb Download PDFInfo
- Publication number
- SK285344B6 SK285344B6 SK79-99A SK7999A SK285344B6 SK 285344 B6 SK285344 B6 SK 285344B6 SK 7999 A SK7999 A SK 7999A SK 285344 B6 SK285344 B6 SK 285344B6
- Authority
- SK
- Slovakia
- Prior art keywords
- cells
- pharmaceutical compositions
- mcf
- treatment
- preparation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/20—Spiro-condensed ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
- C07C211/29—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/32—Oxygen atoms
- C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9609531A FR2751645B1 (fr) | 1996-07-29 | 1996-07-29 | Amines pour la fabrication de medicaments destines a empecher la proliferation de cellules tumorales |
PCT/FR1997/001409 WO1998004251A1 (fr) | 1996-07-29 | 1997-07-28 | Amines pour la fabrication de medicaments destines a empecher la proliferation de cellules tumorales |
Publications (2)
Publication Number | Publication Date |
---|---|
SK7999A3 SK7999A3 (en) | 2000-01-18 |
SK285344B6 true SK285344B6 (sk) | 2006-11-03 |
Family
ID=9494593
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SK79-99A SK285344B6 (sk) | 1996-07-29 | 1997-07-28 | Použitie cis-N-cyklohexyl-N-etyl-[3-(3-chlór-4- cyklohexylfenyl)alyl]amínu na prípravu farmacetických kompozícií na liečbu proliferatívnych chorôb |
Country Status (31)
Country | Link |
---|---|
US (1) | US6235791B1 (xx) |
EP (1) | EP0917464B1 (xx) |
JP (1) | JP3538431B2 (xx) |
KR (1) | KR100315559B1 (xx) |
CN (1) | CN1154483C (xx) |
AR (1) | AR008090A1 (xx) |
AT (1) | ATE266392T1 (xx) |
AU (1) | AU735948B2 (xx) |
BR (1) | BR9711606A (xx) |
CA (1) | CA2261827C (xx) |
CZ (1) | CZ294266B6 (xx) |
DE (1) | DE69729099T2 (xx) |
DK (1) | DK0917464T3 (xx) |
EE (1) | EE03851B1 (xx) |
ES (1) | ES2221061T3 (xx) |
FR (1) | FR2751645B1 (xx) |
HU (1) | HU224346B1 (xx) |
ID (1) | ID17707A (xx) |
IL (1) | IL127922A (xx) |
IS (1) | IS2049B (xx) |
MY (1) | MY120426A (xx) |
NO (1) | NO322897B1 (xx) |
NZ (1) | NZ333957A (xx) |
PT (1) | PT917464E (xx) |
RU (1) | RU2176502C2 (xx) |
SI (1) | SI0917464T1 (xx) |
SK (1) | SK285344B6 (xx) |
TR (1) | TR199900161T2 (xx) |
UA (1) | UA61080C2 (xx) |
WO (1) | WO1998004251A1 (xx) |
ZA (1) | ZA976697B (xx) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2143403B1 (es) * | 1998-03-13 | 2001-01-01 | Consejo Superior Investigacion | Derivados de ciclopropenilaminas como agentes anticancerosos. |
GB9814036D0 (en) | 1998-06-29 | 1998-08-26 | Univ Dundee | Materials and methods relating to the induction of apoptosis in target cells |
FR2794742B1 (fr) | 1999-06-11 | 2005-06-03 | Sanofi Synthelabo | Nouveaux derives du benzene, un procede pour leur preparation et les compositions pharmaceutiques les contenant |
FR2795724B1 (fr) | 1999-07-02 | 2002-12-13 | Sanofi Synthelabo | Nouveaux derives du benzene, un procede pour leur preparation et les compositions pharmaceutiques les contenant |
FR2803593B1 (fr) * | 2000-01-06 | 2002-02-15 | Sanofi Synthelabo | Nouvelles tetrahydropyridines, procede pour leur preparation et compositions pharmaceutiques les contenant |
ES2266618T3 (es) * | 2001-08-23 | 2007-03-01 | Bayer Cropscience S.A. | Propargilaminas substituidas. |
FR2887454B1 (fr) * | 2005-06-28 | 2009-06-05 | Sanofi Aventis Sa | Combinaisons antitumorales contenant des derives du taxane et des sigma ligands |
KR20090024811A (ko) | 2006-06-23 | 2009-03-09 | 아보트 러보러터리즈 | 히스타민 h3 수용체 조절제로서의 사이클로프로필 아민 유도체 |
US9108948B2 (en) * | 2006-06-23 | 2015-08-18 | Abbvie Inc. | Cyclopropyl amine derivatives |
CN101669030B (zh) | 2007-03-08 | 2016-01-13 | 小利兰·斯坦福大学托管委员会 | 线粒体醛脱氢酶2调节剂和其使用方法 |
US8354435B2 (en) | 2008-09-08 | 2013-01-15 | The Board Of Trustees Of The Leland Stanford Junior University | Modulators of aldehyde dehydrogenase activity and methods of use thereof |
KR20110082180A (ko) | 2008-10-28 | 2011-07-18 | 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 | 알데히드 탈수소효소의 조절자 및 그것의 사용방법 |
US9186353B2 (en) | 2009-04-27 | 2015-11-17 | Abbvie Inc. | Treatment of osteoarthritis pain |
WO2012037258A1 (en) | 2010-09-16 | 2012-03-22 | Abbott Laboratories | Processes for preparing 1,2-substituted cyclopropyl derivatives |
US10457659B2 (en) | 2011-04-29 | 2019-10-29 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for increasing proliferation of adult salivary stem cells |
RU2015106915A (ru) * | 2012-08-01 | 2016-09-20 | Мерк Шарп И Доум Корп. | МОДУЛЯТОРЫ α7 НИКОТИНОВОГО АЦЕТИЛХОЛИНОВОГО РЕЦЕПТОРА И ИХ ПРИМЕНЕНИЕ |
CN105358531B (zh) | 2013-03-14 | 2017-11-14 | 利兰-斯坦福大学初级学院的董事会 | 线粒体醛脱氢酶‑2调节剂和其使用方法 |
SG11201808220VA (en) | 2016-03-22 | 2018-10-30 | Merck Sharp & Dohme | Allosteric modulators of nicotinic acetylcholine receptors |
MX2023003033A (es) | 2020-09-17 | 2023-06-09 | Meletios Therapeutics | Compuestos y metodos para el tratamiento de infecciones por virus. |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3674832A (en) * | 1968-08-22 | 1972-07-04 | Schering Corp | Cyclopropane carboxylic acid derivatives |
FR2132547A1 (en) | 1971-04-08 | 1972-11-24 | Clin Byla Ets | Substd phenyl alkyl or alkenyl amides - useful as analgesics and antiinflammatories |
GB1475314A (en) * | 1973-11-02 | 1977-06-01 | Cm Ind | Phenyl-propylamine derivatives |
US4104383A (en) | 1973-11-02 | 1978-08-01 | C M Industries | Derivatives of phenylpropenylamine |
IT1113391B (it) | 1979-05-09 | 1986-01-20 | Maggioni Farma | Derivati fenilcicloesanici ad attivita' antidepressiva |
US4537902A (en) * | 1979-06-11 | 1985-08-27 | Merck & Co., Inc. | 4-Substituted-3-hydroxy-3-pyrroline-2,5-dione inhibitors of glycolic acid oxidase |
FR2641276B1 (fr) * | 1988-12-30 | 1991-07-12 | Sanofi Sa | Derives du benzene, leur preparation et les compositions pharmaceutiques en contenant |
JP2814694B2 (ja) | 1989-07-21 | 1998-10-27 | セイコーエプソン株式会社 | 識別コード読み書き構造及びその装置及びその方法 |
FR2663328B1 (fr) * | 1990-06-14 | 1994-08-05 | Sanofi Sa | Derives d'hexahydroazepines, un procede pour leur preparation et compositions pharmaceutiques les contenant. |
FR2694287B1 (fr) * | 1992-07-31 | 1994-09-16 | Jouveinal Inst Rech | Nouvelles cycloalkylalkylamines ligands aux récepteurs sigma, leur procédé de préparation et leur application en thérapeutique. |
FR2713639B1 (fr) * | 1993-12-09 | 1996-08-30 | Irj | Nouveaux dérivés de 2-arylalkényl-azacycloalkanes ligands aux récepteurs sigma, leur procédé de préparation et leur application en thérapeutique. |
FR2724656B1 (fr) * | 1994-09-15 | 1996-12-13 | Adir | Nouveaux derives du benzopyranne, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
FR2725445B1 (fr) * | 1994-10-10 | 1996-10-31 | Adir | Nouveaux derives a structure 1-arylalkenyl 4-aryl alkyl piperazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
US5919934A (en) * | 1997-02-19 | 1999-07-06 | The George Washington University | Compounds, compositions, and methods for cancer imaging and therapy |
-
1996
- 1996-07-29 FR FR9609531A patent/FR2751645B1/fr not_active Expired - Fee Related
-
1997
- 1997-07-28 CA CA002261827A patent/CA2261827C/fr not_active Expired - Fee Related
- 1997-07-28 HU HU9902806A patent/HU224346B1/hu not_active IP Right Cessation
- 1997-07-28 CN CNB971968853A patent/CN1154483C/zh not_active Expired - Fee Related
- 1997-07-28 US US09/230,643 patent/US6235791B1/en not_active Expired - Fee Related
- 1997-07-28 ES ES97935643T patent/ES2221061T3/es not_active Expired - Lifetime
- 1997-07-28 KR KR1019997000698A patent/KR100315559B1/ko not_active IP Right Cessation
- 1997-07-28 EP EP97935643A patent/EP0917464B1/fr not_active Expired - Lifetime
- 1997-07-28 AT AT97935643T patent/ATE266392T1/de not_active IP Right Cessation
- 1997-07-28 UA UA99021083A patent/UA61080C2/uk unknown
- 1997-07-28 SK SK79-99A patent/SK285344B6/sk not_active IP Right Cessation
- 1997-07-28 SI SI9730649T patent/SI0917464T1/xx unknown
- 1997-07-28 NZ NZ333957A patent/NZ333957A/xx unknown
- 1997-07-28 CZ CZ1999242A patent/CZ294266B6/cs not_active IP Right Cessation
- 1997-07-28 AR ARP970103405A patent/AR008090A1/es unknown
- 1997-07-28 WO PCT/FR1997/001409 patent/WO1998004251A1/fr active IP Right Grant
- 1997-07-28 PT PT97935643T patent/PT917464E/pt unknown
- 1997-07-28 ID IDP972614A patent/ID17707A/id unknown
- 1997-07-28 DE DE69729099T patent/DE69729099T2/de not_active Expired - Fee Related
- 1997-07-28 JP JP50856798A patent/JP3538431B2/ja not_active Expired - Fee Related
- 1997-07-28 BR BR9711606A patent/BR9711606A/pt not_active Application Discontinuation
- 1997-07-28 EE EEP199900029A patent/EE03851B1/xx not_active IP Right Cessation
- 1997-07-28 AU AU38551/97A patent/AU735948B2/en not_active Ceased
- 1997-07-28 IL IL12792297A patent/IL127922A/xx not_active IP Right Cessation
- 1997-07-28 TR TR1999/00161T patent/TR199900161T2/xx unknown
- 1997-07-28 RU RU99104150/14A patent/RU2176502C2/ru not_active IP Right Cessation
- 1997-07-28 ZA ZA9706697A patent/ZA976697B/xx unknown
- 1997-07-28 DK DK97935643T patent/DK0917464T3/da active
- 1997-07-29 MY MYPI97003451A patent/MY120426A/en unknown
-
1999
- 1999-01-19 IS IS4946A patent/IS2049B/is unknown
- 1999-01-28 NO NO19990401A patent/NO322897B1/no not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SK285344B6 (sk) | Použitie cis-N-cyklohexyl-N-etyl-[3-(3-chlór-4- cyklohexylfenyl)alyl]amínu na prípravu farmacetických kompozícií na liečbu proliferatívnych chorôb | |
EP0616812B1 (en) | Combination with anti-hormonal compounds and binding molecules for the treatment of cancer | |
Hardwicke et al. | GSK1070916, a potent Aurora B/C kinase inhibitor with broad antitumor activity in tissue culture cells and human tumor xenograft models | |
JP6810146B2 (ja) | 受容体媒介化学療法による癌の治療のためのペプチド化合物およびペプチドコンジュゲート | |
US20040019060A1 (en) | Sigma receptor ligands and their medical uses | |
US20100305129A1 (en) | Compositions and methods for inhibiting growth and metastasis of melanoma | |
EP1653943B3 (en) | Catechol derivatives for the treatment of cancer | |
WO2003073999A2 (en) | Pini-modulating compounds and methods of use thereof | |
KR20010102514A (ko) | 알레르기성 질환 치료용 제이에이케이-3 억제제 | |
Arnst et al. | Colchicine binding site agent DJ95 overcomes drug resistance and exhibits antitumor efficacy | |
TW200804350A (en) | Aryl-substituted quinazolones, and uses thereof | |
US20090041767A1 (en) | Pharmaceutical combinations | |
US9867807B2 (en) | Compositions and methods for drug-sensitization or inhibition of a cancer cell | |
Gardette et al. | Evaluation of two 125 I-radiolabeled acridine derivatives for Auger-electron radionuclide therapy of melanoma | |
KR20230118147A (ko) | 전립선암 치료 방법 | |
Pirker et al. | Enhancement of the activity of immunotoxins by analogues of verapamil | |
IL95875A (en) | Pharmaceutical compositions containing analogues of illudin m and s for inhibiting tumor cell growth | |
WO2005034856A2 (en) | Targeted drug-formaldehyde conjugates and methods of making and using the same | |
US7781398B2 (en) | Drug comprising synthetic peptide analogs for the treatment of cancer | |
CN101083990A (zh) | 破坏brca2-rad51相互作用的组合物和方法 | |
US20230321062A1 (en) | Combination therapies | |
WO2004002429A2 (en) | Methods of inhibiting pin1-associated states using a fredericamycin a compound | |
SZELĄG | Influence of N, N− Diethyl− 2−[4−(Phenylmethyl) Phenoxy] Ethanamine (DPPE) on the Proliferation of Selected Cell Lines in vitro | |
Bodmer | 31st Annual Meeting of the British Association of Cancer Research and the 5th Annual Meeting of the Association of Cancer Physicians | |
Jianga et al. | GDC-0973 Inhibitor. com |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Patent lapsed due to non-payment of maintenance fees |
Effective date: 20090728 |